Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GeoVax Labs ( (GOVX) ) has provided an announcement.
GeoVax Labs held its annual meeting of stockholders on June 5, 2025, where they discussed key proposals impacting the company’s governance and financial strategies. The stockholders elected a slate of seven directors, approved the 2025 Stock Incentive Plan, agreed to the issuance of shares upon warrant exercise, and ratified Wipfli LLP as the independent auditor for the fiscal year ending December 31, 2025. These decisions are expected to influence GeoVax Labs’ operational and strategic direction, potentially affecting its market positioning and stakeholder interests.
The most recent analyst rating on (GOVX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
GeoVax Labs is navigating substantial financial and operational challenges, reflected in its low financial performance score. While there are positive developments in vaccine advancements and strategic partnerships, the negative impact of the BARDA contract termination and bearish technical indicators weigh heavily on the overall score.
To see Spark’s full report on GOVX stock, click here.
More about GeoVax Labs
Average Trading Volume: 443,938
Technical Sentiment Signal: Sell
Current Market Cap: $15.95M
See more data about GOVX stock on TipRanks’ Stock Analysis page.